Spring Research Update Meeting 2025
Our 2025 Spring Research Update Meeting will take place at BMA House, home of the British Medical Association, in Tavistock Square, London on 24 March where we invite guests to an inspiring agenda of some of the most up to date news of our funded...
Learn more
Further funding announced for clinical studies and data investigation
After a year of disruption, clinical research has now restarted and lab-based research is getting back on track. Cure Parkinson’s is delighted to report that it is investing significant funds into research in the first quarter of 2021.
An important ruling for aducanumab
On the 7th June, the US FDA held a special meeting and approved an experimental drug called aducanumab for the treatment of Alzheimer’s. This decision represents a major milestone for neurodegenerative research.
Cure Parkinson’s funds new nerve growth factors for Parkinson’s
Nerve growth or neurotrophic factors such as CDNF and GDNF are proteins that support neurons and encourage their growth and survival during development. There has been considerable preclinical research exploring their potential use in Parkinson’s
The exenatide phase 3 study protocol
Researchers conducting the phase 3 ‘Exenatide PD3’ clinical trial have published the protocol of the study, which outlines the details of the trial. Cure Parkinson’s is supporting two sub-studies within the phase 3 trial.
Eric Mytton and Dom Kelly Run the West Highland Way for Cure Parkinson’s
From 23-27 May, Eric Mytton and his good friend Dom Kelly took on the amazing challenge of running the iconic West Highland Way in Scotland in support of Cure Parkinson’s and The MS Trust, two charities close to both of their hearts. After taking up…